Seizures Clinical Trials

Find Seizures Clinical Trials Near You

Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

Cannabidiol (CBD), one of the most prevalent cannabinoids in cannabis (marijuana) has been shown to reduce alcohol withdrawal symptoms in laboratory animals. In people without alcohol use disorder (AUD), CBD has been show to be effective in reducing anxiety, sleep problems, and seizures; all of these are common symptoms of alcohol withdrawal. This randomized placebo-controlled clinical trial will evaluate the potential of CBD to improve alcohol withdrawal symptoms and reduce craving during acute abstinence among individuals with moderate-to-severe AUD. Adult participants with moderate-to-severe AUD will be admitted to an inpatient research unit at the Johns Hopkins Hospital for a 5-day, 4-night stay that includes alcohol abstinence with management of their alcohol withdrawal. In addition to standard care, participants will receive CBD or placebo (no CBD), complete assessments of withdrawal, sleep quality and provide breath and blood samples.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 65
Healthy Volunteers: f
View:

• Meets DSM-5 criteria Moderate or Severe Alcohol Use Disorder

• Age 21-65

• Report at least one prior episode of alcohol withdrawal symptoms at least one day in duration that caused significant impairment in functioning (i.e., unable to attend work or engage in typical activities) AND/OR required medications to manage symptoms.

• Report at least 21 days of heavy drinking (four or more drinks for women, five or more drinks for men) over the last 28 days.

• if female of childbearing potential who has not had a sterilization procedure:

• Negative human chorionic gonadotropin (hCG) on qualitative urine pregnancy screen

• Agree to use a highly effective method of contraception (e.g. hormonal contraception, intrauterine device, double-barrier method) for at least five days prior to administration of the study drug and throughout the duration of the study

• Shipley vocabulary score \> 18, corresponding to 5th grade reading level.

• Demonstrated understanding of informed consent and ability to consent to participation in the study.

Locations
United States
Maryland
Behavioral Pharmacology Research Unit
RECRUITING
Baltimore
Contact Information
Primary
David Woliinsky, MD
dwolins2@jhmi.edu
(410) 550-0047
Backup
Elise M Weerts, PhD
eweerts@jhmi.edu
410-550-2781
Time Frame
Start Date: 2026-11-01
Estimated Completion Date: 2030-10-31
Participants
Target number of participants: 105
Treatments
Active_comparator: 10 mg/kg CBD
low dose CBD
Active_comparator: 20 mg/kg CBD
high dose CBD
Placebo_comparator: placebo
Placebo (no CBD)
Related Therapeutic Areas
Sponsors
Collaborators: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Leads: Johns Hopkins University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials